Kymera Therapeutics Inc (KYMR)vsRevolution Medicines Inc (RVMD)
KYMR
Kymera Therapeutics Inc
$74.13
-0.64%
HEALTHCARE · Cap: $7.09B
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Kymera Therapeutics Inc generates 6837% more annual revenue ($51.48M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. KYMR earns a higher WallStSmart Score of 34/100 (F).
KYMR
Avoid34
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-56.8%
Fair Value
$52.46
Current Price
$74.13
$21.67 premium
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 55.5% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -20.5% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KYMR
The strongest argument for KYMR centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : KYMR
The primary concerns for KYMR are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
KYMR profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
KYMR carries more volatility with a beta of 2.03 — expect wider price swings.
KYMR is growing revenue faster at 55.5% — sustainability is the question.
KYMR generates stronger free cash flow (-89M), providing more financial flexibility.
Bottom Line
KYMR scores higher overall (34/100 vs 24/100) and 55.5% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kymera Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?